Somatoform Disorders:  
When symptoms suggest a physical disorder, which is actually not present & present & the patient does not get better despite the doctor's best symptomatic treatment.
Significantly higher incidence:

Complications:
Unnecessary & repetitive investigations & surgery
Drug Dependence.
High cost of unnecessary treatment. Continuous change of doctors
Studies have shown that from a quarter to one half of the patients attending general practitioners actually suffering from Somatoform Disorders.
Rer: Court C.Report urges better psychological care. BMJ 1995:310:1027.
The DSM IV describes 5 subtypes of Somatoform disorders
1 Body dysmorphic disorders 2 Pain disorders 3 Hypochondriasis 4 Conversion disorders
And the most common
5 SOMATIZATION DISORDERS
WITH FOLLOWING SYMPTOMS

GIT Symptoms:

  • Nausea, Vomiting
  • Abdominal Pain
  • Heart Burns
  • Gas, Glatulence
  • Diarrhoea

Sexual Symptoms:

  • Burning sensation in sexual organs
  • Pain during intercourse
  • Impotency

 

Genitourinary Symptoms:

  • Urinary retention or difficulty in urinating.
  • increased frequency of urination.

 

Pseudoneurological Symptoms:

  • Amnesia Blurred vision
  • Difficulty in swallowing
  • Muscle weekness or fatugue

Cadiopulmonary Symptoms:

  • Shortness of breath
  • Palpitation
  • Chest Pain

 

Pain Symptoms:

  • Pain of extremities
  • Back Pain
  • Joint Pain
  • Other Pains
The only psychotropic drug indicated to the treatment of somatoform disorders
 
More effective than SSRIs and Benzodiazepines.

Variation in the number of SD symptoms with levo-sulpiride or placebo, before and after cross-over (p<0.007).
Trial Setup:
No.of patients:74 Dose: 50 mg b.i.d.Result:
Levopraid 50 has proved a significantly better efficacy compared with placebo in reducing the number & severity of somatoform disorder symptoms.
LEVOPRAID 50 Acts Faster
Than Amitriptyline in Depression 4
 
LEVOPRAID 50 Achieves Higher
Clinical Response Than Mianserin 5
 
Results:
LEVOPRAID 50 showed antidepressant activity comparable to Amitriptyline but its onset of effects was faster.		   No.of Patients: 41(21 on Levosulpiride and 20 on Mianserin) suffering from major depression or dysthymia. Duration of Treatment: 60 days.
Dose: Levosulpiride 200-300 mg/day, Mianserin 90-120 mg/day
Safety Profile:        
Teh safety of Levosulpiride (LEVOPRAID 50 tablet bid) was assessed in 2145 patients with depressive disorders, over a period of 2-3 months at 60 Psychiatric centres all over italy.
  • The incidence of adverse reactions was very low
  • The drop out of patients due to side effects was only 0.49%.
  • No clinically noteworthy laboratory or ECG changes.3
  
Dosage:    

1 tablet of LEVOPRAID 50
2-3 times daily.

  
 
 
 
Download  
       
       
Home | About Us | Research | Employment | Contact Us